National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases
about
What's new in multidrug-resistant pathogens in the ICU?Analysis of drug resistance determinants in Klebsiella pneumoniae isolates from a tertiary-care hospital in Beijing, ChinaPhenotypic and molecular characterization of multidrug resistant Klebsiella pneumoniae isolated from a university teaching hospital, ChinaThe Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the EvidenceCost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.Use of imipenem to detect KPC, NDM, OXA, IMP, and VIM carbapenemase activity from gram-negative rods in 75 minutes using liquid chromatography-tandem mass spectrometryPediatric multicenter evaluation of the Verigene gram-negative blood culture test for rapid detection of inpatient bacteremia involving gram-negative organisms, extended-spectrum beta-lactamases, and carbapenemases.Impact of extended-spectrum β-lactamase production on treatment outcomes of acute pyelonephritis caused by escherichia coli in patients without health care-associated risk factors.Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship.Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections.Detection of extended-spectrum β-lactamase and Klebsiella pneumoniae Carbapenemase genes directly from blood cultures by use of a nucleic acid microarrayTransmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting.Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance TrendEstimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012.Intra-abdominal Infections: The Role of Anaerobes, Enterococci, Fungi, and Multidrug-Resistant Organisms.Predictors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli infection in a Midwestern communityMajor variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method.Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy.Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.The role of antimicrobial stewardship in curbing carbapenem resistance.The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae.The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis.Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.[Management of multiresistant bacteria in urology].ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.Rapid detection of carbapenemase activity through monitoring ertapenem hydrolysis in Enterobacteriaceae with LC-MS/MS.Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance daScientific Opinion on the public health risks of bacterial strains producing extended-spectrum β-lactamases and/or AmpC β-lactamases in food and food-producing animalsScientific Opinion on Carbapenem resistance in food animal ecosystemsTowards a Definition for Health Care-Associated Infection.
P2860
Q28071346-F88B2763-0763-4726-8D6C-3C2D134FC199Q28481714-B62D0F31-E46B-436F-A9D3-AE186C681F95Q28537970-148C82E6-2C6A-4698-BCB2-D38FB900D0FAQ33564316-5741855A-AA33-4CE5-B95E-1DD4321316D1Q33617939-0F3BCE12-5AB7-4FA3-9CB3-110728C65900Q33900038-C0E940A3-437F-41A1-BF5A-2C0A1FF66DD7Q33900098-3FE4FF92-60BF-4505-8111-072FE20255B2Q35168939-31966194-88E1-4CEC-88E2-71BCD2BADA52Q35207767-F98F3346-4D25-4D3A-BBC2-402072ED34CCQ35791188-B9F2CCCD-6408-4DF2-9E99-03364B2103E5Q36172336-FF4B5E3A-2FFC-49BF-AF6B-BC67560F8E0AQ36218305-E6AAC4A3-4AE0-4EDD-AF5C-9F8BDBC69AA4Q36969726-E463AC39-BE6F-42D2-823E-5E6EB43A3C9CQ36969909-C24AC5F0-09E8-4FF0-9CA2-DE26DEB9604AQ37498492-5253E670-3F5E-468C-B979-09CBA58B4F57Q37517993-FB3C9812-6EDF-4C00-A80B-86D37059B7F7Q37562416-6D09A0DB-3DE1-4F68-AE16-E01E026B1C68Q37713697-02B4C7A8-424B-4829-8024-4DA00BF9E1CCQ37970757-36B96067-18AB-4B8F-AE8E-A9EFA00659C2Q37991287-D4568401-B08E-4C88-9714-3E561F174CCBQ38048860-BF0E8CCC-05C4-4981-8481-3BD101FD2C98Q38125493-2A0CB6D3-2AAC-4B7C-9479-E6ADCFD2EE06Q38497797-2D602BB7-8976-4830-9A91-CF1F9706DC72Q38966337-1B69D99B-F060-4629-8F83-E5D4E8E5D584Q40131042-251532C7-F25F-4A1B-8F73-C26A2253EA69Q40203385-04F2E23E-1768-41A2-B230-B9ABD6E06A3DQ40217511-9D1892D8-05FA-44C1-95F3-12347CC645D5Q41195975-6402E2AB-041A-4F33-B473-E1DD9DFAFD76Q41217004-10249F77-8A2D-41BE-9BE6-46A168FF0247Q41750938-4A466A4D-9241-4B73-BEEC-CFAAB07EB6AEQ43971402-05E50733-0917-4664-801D-713EBCC32764Q45351595-F0986E82-275D-4D14-9764-0BA2D0E21F4FQ47150482-087631A2-67D5-440E-9BEE-82E61CB87A6EQ47154044-F4FD9A44-2E13-4C50-A1E9-C0E3381CEAB8Q55315095-9E6EDECD-E27C-4052-9E95-FC31153A762A
P2860
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
National multicenter study of ...... ended-spectrum beta-lactamases
@ast
National multicenter study of ...... ended-spectrum beta-lactamases
@en
National multicenter study of ...... ended-spectrum beta-lactamases
@nl
type
label
National multicenter study of ...... ended-spectrum beta-lactamases
@ast
National multicenter study of ...... ended-spectrum beta-lactamases
@en
National multicenter study of ...... ended-spectrum beta-lactamases
@nl
prefLabel
National multicenter study of ...... ended-spectrum beta-lactamases
@ast
National multicenter study of ...... ended-spectrum beta-lactamases
@en
National multicenter study of ...... ended-spectrum beta-lactamases
@nl
P2093
P2860
P356
P1476
National multicenter study of ...... ended-spectrum beta-lactamases
@en
P2093
Danny Alon
Dror Marchaim
Eyal Braun
Galia Rahav
Hana Sprecher
Israel Potasman
Maya Korem
Michael Giladi
Mitchell J Schwaber
P2860
P304
P356
10.1128/AAC.00565-10
P407
P577
2010-09-13T00:00:00Z